Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase NA 1Phase 3 1Phase 1/2 1

Status

Recruiting 3Not yet recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 7

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 5Lymphoid 1Gynecologic 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Metastatic Breast Cancer With a Isolated Brain Progression 1Lymphoma 1Hodgkin Disease 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × Interventional × Biosimilar Pharmaceuticals × Clear all
NCT07220135 2026-05-06

NeoTHERa

University of Kansas Medical Center

Phase 2 Recruiting
100 enrolled
Breast

Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Fudan University

Phase 2 Recruiting
160 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07393425 2026-02-06

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
50 enrolled
Breast

Breast Neoplasms

NCT07246317 2025-11-28

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
188 enrolled
Breast

Breast Neoplasms

NCT05041842 2025-11-17

InTTercePT

UNICANCER

Phase 2 Active not recruiting
53 enrolled
Breast

Metastatic Breast Cancer With a Isolated Brain Progression

NCT06650709 2024-10-23

NEOCATS

British Columbia Cancer Agency

Phase 2 Not yet recruiting
40 enrolled
Gynecologic

Ovarian Neoplasms

NCT00003820 2017-04-20

Rituximab in Treating Patients With Hodgkin's Lymphoma

Stanford University

Phase 2 Completed
39 enrolled 9 charts
Lymphoid

Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡